Revvity Valuation
Is RVTY * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RVTY * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RVTY * (MX$2420) is trading above our estimate of fair value (MX$2379.16)
Significantly Below Fair Value: RVTY * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RVTY *?
Key metric: As RVTY * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is RVTY *'s PE Ratio? | |
|---|---|
| PE Ratio | 46.4x |
| Earnings | US$353.45m |
| Market Cap | US$16.42b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.1x |
| Enterprise Value/EBITDA | 17.1x |
| PEG Ratio | 3.1x |
Price to Earnings Ratio vs Peers
How does RVTY *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 106.6x | ||
DIM Sartorius Stedim Biotech | 108.5x | 31.9% | €17.4b |
DIVISLAB Divi's Laboratories | 87.8x | 23.7% | ₹1.6t |
SRT3 Sartorius | 193.9x | 36.4% | €13.6b |
WAT Waters | 36.1x | 8.6% | US$22.2b |
RVTY * Revvity | 46.4x | 15.0% | Mex$16.4b |
Price-To-Earnings vs Peers: RVTY * is expensive based on its Price-To-Earnings Ratio (46.4x) compared to the peer average (30.6x).
Price to Earnings Ratio vs Industry
How does RVTY *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: RVTY * is expensive based on its Price-To-Earnings Ratio (46.4x) compared to the Global Life Sciences industry average (32.2x).
Price to Earnings Ratio vs Fair Ratio
What is RVTY *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 46.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RVTY *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a
Merck KGaA
€62.2b
Operates as a science and technology company in Germany.
MRK1 N
€3,299.85
7D
0%
1Y
n/a